摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3-chloro-phenyl)-{2-[4-(4-nitro-phenyl)-piperazin-1-yl]-5-oxo-6,7-dihydro-5H-5λ4-thieno[3,2-d]pyrimidin-4-yl}-amine trifluoroacetate

中文名称
——
中文别名
——
英文名称
(3-chloro-phenyl)-{2-[4-(4-nitro-phenyl)-piperazin-1-yl]-5-oxo-6,7-dihydro-5H-5λ4-thieno[3,2-d]pyrimidin-4-yl}-amine trifluoroacetate
英文别名
{2-[4-(4-amino-phenyl)-piperazin-1-yl]-5-oxo-6,7-dihydro-5H-5λ4-thieno[3,2-d]pyrimidin-4-yl}-(3-chloro-phenyl)-amine trifluoroacetate;{2-[4-(4-amino-phenyl)-piperazin-1-yl]-5-oxo-6,7-dihydro-5H-5lambda4-thieno[3,2-d]pyrimidin-4-yl}-(3-chloro-phenyl)-amine trifluoroacetate;2-[4-(4-aminophenyl)piperazin-1-yl]-N-(3-chlorophenyl)-5-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-4-amine;2,2,2-trifluoroacetic acid
(3-chloro-phenyl)-{2-[4-(4-nitro-phenyl)-piperazin-1-yl]-5-oxo-6,7-dihydro-5H-5λ4-thieno[3,2-d]pyrimidin-4-yl}-amine trifluoroacetate化学式
CAS
——
化学式
C2HF3O2*C22H23ClN6OS
mdl
——
分子量
569.007
InChiKey
QHFQRNUQMGKIIO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.08
  • 重原子数:
    38
  • 可旋转键数:
    4
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    144
  • 氢给体数:
    3
  • 氢受体数:
    13

反应信息

点击查看最新优质反应信息

文献信息

  • Dihydrothienopyrimidines for the treatment of inflammatory Diseases
    申请人:POUZET Pascale
    公开号:US20120108534A1
    公开(公告)日:2012-05-03
    The invention relates to new dihydrothienopyrimidine of formula 1 , as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 and R 3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    本发明涉及一种新的二氢噻唑嘧啶化合物,其化学式为1,以及其药物学上可接受的盐、对映异构体、对映体、外消旋体、水合物或溶剂化物,其中X为SO或SO2,但优选为SO,R1、R2和R3在说明中给出了其含义,该化合物适用于治疗呼吸或胃肠道不适或疾病、关节、皮肤或眼睛的炎症性疾病、周围或中枢神经系统疾病或癌症,以及含有这些化合物的制药组合物。
  • 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases
    申请人:Boehringer Ingelheim International GmbH
    公开号:US08114878B2
    公开(公告)日:2012-02-14
    The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO2, but preferably SO, and wherein R1, R2 and R3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    本发明涉及公式1的新二氢噻唑嘧啶,以及药学上可接受的盐,对映异构体,对映体混合物,水合物或其溶剂化物。其中X为SO或SO2,但最好为SO,R1,R2和R3的含义如说明书所述,并且适用于治疗呼吸或消化不适或疾病,关节,皮肤或眼睛的炎症性疾病,周围或中枢神经系统疾病或癌症,以及包含这些化合物的制药组合物。
  • Dihydrothienopyrimidines for the treatment of inflammatory diseases
    申请人:Pouzet Pascale
    公开号:US08604039B2
    公开(公告)日:2013-12-10
    The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO2, but preferably SO, and wherein R1, R2 and R3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    本发明涉及一种新的二氢噻唑嘧啶化合物,其化学式为1,以及其药理学上可接受的盐、对映体、立体异构体、外消旋体、水合物或溶剂化物,其中X为SO或SO2,但最好为SO,R1、R2和R3的含义如说明中所述,适用于治疗呼吸或胃肠不适或疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统的疾病或癌症,以及包含这些化合物的制药组合物。
  • 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases
    申请人:POUZET Pascale
    公开号:US20140005154A1
    公开(公告)日:2014-01-02
    The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 and R 3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    本发明涉及式1的新的二氢噻唑嘧啶,以及其药学上可接受的盐、对映异构体、对映体混合物、水合物或溶剂化物,其中X为SO或SO2,但优选为SO,R1、R2和R3具有所述描述中给出的含义,适用于治疗呼吸或消化不适或疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症,以及含有这些化合物的制药组合物。
  • Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
    申请人:Boehringer Ingelheim Pharma GmbH & Co. KG
    公开号:EP1847543A1
    公开(公告)日:2007-10-24
    Die Erfindung betrifft neue Dihydrothienopyrimidine der Formel 1, sowie pharmakologisch verträgliche Salze, Diastereomere, Enantiomere, Racemate, Hydrate oder Solvate davon, die geeignet sind zur Behandlung von Atemwegs- oder gastrointestinalen Beschwerden oder Erkrankungen, entzündlichen Erkrankungen der Gelenke, der Haut oder der Augen, Erkrankungen des periphären oder zentralen Nervensystems oder Krebserkrankungen, sowie pharmazeutische Zusammensetzungen die diese Verbindungen beinhalten.
    本发明涉及式 1 的新型二氢噻吩嘧啶及其药理学上可接受的盐、非对映异构体、对映体、外消旋体、水合物或溶剂、 适用于治疗呼吸道或胃肠道不适或疾病,关节、皮肤或眼睛炎症,外周或中枢神经系统疾病或癌症,以及含有这些化合物的药物组合物。
查看更多